Stocktoria
BillionToOne, Inc. BLLN
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2025-11-06
BillionToOne, Inc. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $305.1M | $152.6M |
| Gross profit | $208.5M | $80.9M |
| R&D expense | $49.4M | $36.6M |
| SG&A expense | $143.1M | $91.5M |
| Operating income | $16.0M | -$47.1M |
| Income tax | $305,000 | $29,000 |
| Net income | $7.5M | -$41.6M |
| EPS (diluted) | $0.14 | $-4.12 |
| Operating cash flow | $24.6M | -$41.4M |
| Free cash flow | $15.7M | -$46.8M |
| Cash & equivalents | $496.0M | $191.5M |
| Inventory | $17.5M | $8.7M |
| Total assets | $632.7M | $302.1M |
| Total liabilities | $152.5M | $134.3M |
| Shareholders' equity | $480.1M | -$251.7M |
Growth · year-over-year · Revenue CAGR 100%
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue growth | +100.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.